200 related articles for article (PubMed ID: 23918749)
1. Hypoxia-inducible factor-1α in vascular smooth muscle regulates blood pressure homeostasis through a peroxisome proliferator-activated receptor-γ-angiotensin II receptor type 1 axis.
Huang Y; Di Lorenzo A; Jiang W; Cantalupo A; Sessa WC; Giordano FJ
Hypertension; 2013 Sep; 62(3):634-40. PubMed ID: 23918749
[TBL] [Abstract][Full Text] [Related]
2. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.
Yamamoto K; Ohishi M; Ho C; Kurtz TW; Rakugi H
Hypertension; 2009 Dec; 54(6):1353-9. PubMed ID: 19822796
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
[TBL] [Abstract][Full Text] [Related]
4. Role of vascular smooth muscle PPARγ in regulating AT1 receptor signaling and angiotensin II-dependent hypertension.
Carrillo-Sepulveda MA; Keen HL; Davis DR; Grobe JL; Sigmund CD
PLoS One; 2014; 9(8):e103786. PubMed ID: 25122005
[TBL] [Abstract][Full Text] [Related]
5. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
[TBL] [Abstract][Full Text] [Related]
6. Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.
Scalera F; Martens-Lobenhoffer J; Bukowska A; Lendeckel U; Täger M; Bode-Böger SM
Hypertension; 2008 Mar; 51(3):696-703. PubMed ID: 18250362
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta.
Tian Q; Miyazaki R; Ichiki T; Imayama I; Inanaga K; Ohtsubo H; Yano K; Takeda K; Sunagawa K
Hypertension; 2009 May; 53(5):798-804. PubMed ID: 19289654
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?
Benson SC; Iguchi R; Ho CI; Yamamoto K; Kurtz TW
J Hypertens; 2008 May; 26(5):973-80. PubMed ID: 18398340
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo.
Benkirane K; Viel EC; Amiri F; Schiffrin EL
Hypertension; 2006 Jan; 47(1):102-8. PubMed ID: 16344371
[TBL] [Abstract][Full Text] [Related]
10. The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice.
Fukuda D; Enomoto S; Hirata Y; Nagai R; Sata M
Biomed Pharmacother; 2010 Dec; 64(10):712-7. PubMed ID: 20970951
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-δ activation.
Li L; Luo Z; Yu H; Feng X; Wang P; Chen J; Pu Y; Zhao Y; He H; Zhong J; Liu D; Zhu Z
Diabetes; 2013 Mar; 62(3):762-74. PubMed ID: 23238297
[TBL] [Abstract][Full Text] [Related]
12. Telmisartan modulates mitochondrial function in vascular smooth muscle cells.
Takeuchi K; Yamamoto K; Ohishi M; Takeshita H; Hongyo K; Kawai T; Takeda M; Kamide K; Kurtz TW; Rakugi H
Hypertens Res; 2013 May; 36(5):433-9. PubMed ID: 23254392
[TBL] [Abstract][Full Text] [Related]
13. Different effects of telmisartan and valsartan on human aortic vascular smooth muscle cell proliferation.
Wang L; Zhao L; Zhang D; Chen JZ; Xue JL
Chin Med J (Engl); 2012 Jun; 125(12):2200-4. PubMed ID: 22884153
[TBL] [Abstract][Full Text] [Related]
14. Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats.
Toba H; Wang J; Ohigashi M; Kobara M; Nakata T
Pharmacology; 2013; 92(5-6):265-75. PubMed ID: 24281041
[TBL] [Abstract][Full Text] [Related]
15. Inhibition or deletion of angiotensin II type 1 receptor suppresses elastase-induced experimental abdominal aortic aneurysms.
Xuan H; Xu B; Wang W; Tanaka H; Fujimura N; Miyata M; Michie SA; Dalman RL
J Vasc Surg; 2018 Feb; 67(2):573-584.e2. PubMed ID: 28434702
[TBL] [Abstract][Full Text] [Related]
16. Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.
Yuen CY; Wong WT; Tian XY; Wong SL; Lau CW; Yu J; Tomlinson B; Yao X; Huang Y
Cardiovasc Res; 2011 Apr; 90(1):122-9. PubMed ID: 21156825
[TBL] [Abstract][Full Text] [Related]
17. Regulation of peroxisome proliferator-activated receptor-γ by angiotensin II via transforming growth factor-β1-activated p38 mitogen-activated protein kinase in aortic smooth muscle cells.
Subramanian V; Golledge J; Heywood EB; Bruemmer D; Daugherty A
Arterioscler Thromb Vasc Biol; 2012 Feb; 32(2):397-405. PubMed ID: 22095985
[TBL] [Abstract][Full Text] [Related]
18. Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma.
Walcher D; Hess K; Heinz P; Petscher K; Vasic D; Kintscher U; Clemenz M; Hartge M; Raps K; Hombach V; Marx N
Hypertension; 2008 Feb; 51(2):259-66. PubMed ID: 18158351
[TBL] [Abstract][Full Text] [Related]
19. Time-dependent PPARγ Modulation of HIF-1α Signaling in Hypoxic Pulmonary Artery Smooth Muscle Cells.
Blum JI; Bijli KM; Murphy TC; Kleinhenz JM; Hart CM
Am J Med Sci; 2016 Jul; 352(1):71-9. PubMed ID: 27432037
[TBL] [Abstract][Full Text] [Related]
20. PPARγ regulates resistance vessel tone through a mechanism involving RGS5-mediated control of protein kinase C and BKCa channel activity.
Ketsawatsomkron P; Lorca RA; Keen HL; Weatherford ET; Liu X; Pelham CJ; Grobe JL; Faraci FM; England SK; Sigmund CD
Circ Res; 2012 Nov; 111(11):1446-58. PubMed ID: 22962432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]